Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice

References

• Andersen A, Lund A, Knop FK, Vilsboll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14(7):390–403. doi:10.1038/s41574-018-0016-2
   PubMed Web of Science ®Google Scholar
• Skov J. Effects of GLP-1 in the kidney. Rev Endocr Metab Disord. 2014;15(3):197–207. doi:10.1007/s11154-014-9287-7
   PubMed Web of Science ®Google Scholar
• Pantalone KM, Munir K, Hasenour CM, et al. Cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists: a comparison of study designs, populations and results. Diabetes Obes Metab. 2020. doi:10.1111/dom.14165
   PubMedGoogle Scholar
• Bonaventura A, Carbone S, Dixon DL, Abbate A, Montecucco F. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists. J Intern Med. 2019;286(1):16–31. doi:10.1111/joim.12890
   PubMedGoogle Scholar
• Heuvelman VD, Van Raalte DH, Smits MM. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. Cardiovasc Res. 2020;116(5):916–930.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi:10.1056/NEJMoa1603827
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130.
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–1529.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi:10.1056/NEJMoa1607141
   PubMed Web of Science ®Google Scholar
• Kristensen SL, Rorth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–785. doi:10.1016/S2213-8587(19)30249-9
   PubMed Web of Science ®Google Scholar
• Gerstein HC, McMurray J, Holman RR. Real-world studies no substitute for RCTs in establishing efficacy. Lancet. 2019;393(10168):210–211.
   PubMedGoogle Scholar
• Yang W, Zilov A, Soewondo P, Bech OM, Sekkal F, Home PD. Observational studies: going beyond the boundaries of randomized controlled trials. Diabetes Res Clin Pract. 2010;88(Suppl 1):S3–9. doi:10.1016/S0168-8227(10)70002-4
   PubMedGoogle Scholar
• Stuart EA, Bradshaw CP, Leaf PJ. Assessing the generalizability of randomized trial results to target populations. Prev Sci. 2015;16(3):475–485. doi:10.1007/s11121-014-0513-z
   PubMed Web of Science ®Google Scholar
• Malmivaara A. Generalizability of findings from randomized controlled trials is limited in the leading general medical journals. J Clin Epidemiol. 2019;107:36–41. doi:10.1016/j.jclinepi.2018.11.014
   PubMedGoogle Scholar
• Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book. 2016;35:185–198. doi:10.1200/EDBK_156686
   PubMedGoogle Scholar
• Sciannameo V, Berchialla P, Orsi E, et al. Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: the case of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2020;22(5):817–827. doi:10.1111/dom.13962
   PubMedGoogle Scholar
• Boye KS, Riddle MC, Gerstein HC, et al. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States. Diabetes Obes Metab. 2019;21(6):1299–1304. doi:10.1111/dom.13649
   PubMedGoogle Scholar
• Collins R, Bowman L, Landray M, Peto R. The magic of randomization versus the myth of real-world evidence. N Engl J Med. 2020;382(7):674–678. doi:10.1056/NEJMsb1901642
   PubMed Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2020;43(2):487–493.
   PubMed Web of Science ®Google Scholar
• Montvida O, Shaw J, Atherton JJ, Stringer F, Paul SK. Long-term trends in antidiabetes drug usage in the U.S.: real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care. 2018;41(1):69–78. doi:10.2337/dc17-1414
   PubMed Web of Science ®Google Scholar
• Fadini GP, Frison V, Simioni N, et al. Changes in the prescription of glucose-lowering medications in patients with type 2 diabetes mellitus after a cardiovascular event: a call to action from the DATAFILE study. J Am Heart Assoc. 2019;8(14):e012244. doi:10.1161/JAHA.119.012244
   PubMedGoogle Scholar
• Franch-Nadal J, Mata-Cases M, Ortega E, et al. Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: prescription according to reimbursement constraints and guideline recommendations in catalonia. J Clin Med. 2019;8(9):1389.
   PubMedGoogle Scholar
• Fadini GP, Frison V, Rigato M, et al. Trend 2010–2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy. Acta Diabetol. 2020;57(3):367–375. doi:10.1007/s00592-019-01445-z
   PubMed Web of Science ®Google Scholar
• Knudsen JS, Baggesen LM, Lajer M, et al. Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: a Danish nationwide population-based study. PLoS One. 2020;15(3):e0229621. doi:10.1371/journal.pone.0229621
   PubMed Web of Science ®Google Scholar
• Revicki DA, Frank L. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. PharmacoEconomics. 1999;15(5):423–434. doi:10.2165/00019053-199915050-00001
   PubMed Web of Science ®Google Scholar
• Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18(4):317–332. doi:10.1111/dom.12596
   PubMed Web of Science ®Google Scholar
• Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117–124. doi:10.1016/S0140-6736(12)61267-7
   PubMed Web of Science ®Google Scholar
• Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258–266. doi:10.2337/dc17-0417
   PubMed Web of Science ®Google Scholar
• Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349–1357. doi:10.1016/S0140-6736(14)60976-4
   PubMed Web of Science ®Google Scholar
• Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37(8):2159–2167. doi:10.2337/dc13-2760
   PubMed Web of Science ®Google Scholar
• Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–286. doi:10.1016/S2213-8587(18)30024-X
   PubMed Web of Science ®Google Scholar
• Hussein H, Zaccardi F, Khunti K, et al. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. Diabetes Obes Metab. 2020;22(7):1035–1046. doi:10.1111/dom.14008
   PubMed Web of Science ®Google Scholar
• Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524–536. doi:10.1111/dom.12849
   PubMed Web of Science ®Google Scholar
• Orme ME, Nguyen H, Lu JY, Thomas SA. Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials. Diabetes Metab Syndr Obes. 2017;10:111–122. doi:10.2147/DMSO.S116810
   PubMed Web of Science ®Google Scholar
• Taylor SI. GLP-1 receptor agonists: differentiation within the class. Lancet Diabetes Endocrinol. 2018;6(2):83–85. doi:10.1016/S2213-8587(17)30413-8
   PubMed Web of Science ®Google Scholar
• Zweck E, Roden M. GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects? Lancet Diabetes Endocrinol. 2019;7(2):89–90. doi:10.1016/S2213-8587(18)30351-6
   PubMedGoogle Scholar
• Morieri ML, Rigato M, Frison V, et al. Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies. Metabolism. 2020;106:154190. doi:10.1016/j.metabol.2020.154190
   PubMedGoogle Scholar
• Fadini GP, Bonora BM, Lapolla A, et al. Comparative effectiveness of exenatide once-weekly versus liraglutide in routine clinical practice: a retrospective multicentre study and meta-analysis of observational studies. Diabetes Obes Metab. 2019;21(5):1255–1260. doi:10.1111/dom.13623
   PubMedGoogle Scholar
• Unni S, Wittbrodt E, Ma J, et al. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):468–473. doi:10.1111/dom.13107
   PubMed Web of Science ®Google Scholar
• Federici MO, McQuillan J, Biricolti G, et al. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Italy: a retrospective cohort study. Diabetes Ther. 2018;9(2):789–801.
   PubMed Web of Science ®Google Scholar
• Otto T, Myland M, Jung H, Lebrec J, Richter H, Norrbacka K. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study. Curr Med Res Opin. 2019;35(5):893–901. doi:10.1080/03007995.2018.1538011
   PubMed Web of Science ®Google Scholar
• Divino V, Boye KS, Lebrec J, DeKoven M, Norrbacka K. GLP-1 RA treatment and dosing patterns among type 2 diabetes patients in six countries: a retrospective analysis of pharmacy claims data. Diabetes Ther. 2019;10(3):1067–1088.
   PubMed Web of Science ®Google Scholar
• Alatorre C, Fernandez Lando L, Yu M, et al. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide. Diabetes Obes Metab. 2017;19(7):953–961. doi:10.1111/dom.12902
   PubMed Web of Science ®Google Scholar
• Brown RE, Abitbol A, Bajaj HS, et al. Patient reported outcomes following initiation of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in a specialist endocrinology practice of the LMC diabetes registry: the PROGRESS-diabetes study. Diabetes Res Clin Pract. 2019;156:107820. doi:10.1016/j.diabres.2019.107820
   PubMedGoogle Scholar
• Amblee A. Mode of administration of dulaglutide: implications for treatment adherence. Patient Prefer Adherence. 2016;10:975–982. doi:10.2147/PPA.S82866
   PubMed Web of Science ®Google Scholar
• Brown RE, Bech PG, Aronson R. Semaglutide once weekly in people with type 2 diabetes: real-world analysis of the Canadian LMC diabetes registry (SPARE study). Diabetes Obes Metab. 2020. doi:10.1111/dom.14117
   Google Scholar
• Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–260. doi:10.1016/S2213-8587(17)30013-X
   PubMed Web of Science ®Google Scholar
• Morieri ML, Rigato M, Frison V, et al. Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: a retrospective multicentre comparative effectiveness study. Diabetes Obes Metab. 2019;21(11):2542–2552.
   PubMedGoogle Scholar
• Gilbert MP, Pratley RE. GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Front Endocrinol (Lausanne). 2020;11:178. doi:10.3389/fendo.2020.00178
   PubMed Web of Science ®Google Scholar
• Carls GS, Tan R, Zhu JY, et al. Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence. Obes Sci Pract. 2017;3(3):342–351. doi:10.1002/osp4.116
   PubMed Web of Science ®Google Scholar
• Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834–844. doi:10.1016/S2213-8587(19)30311-0
   PubMed Web of Science ®Google Scholar
• Lorenzi M, Ploug UJ, Langer J, Skovgaard R, Zoratti M, Jansen J. Liraglutide versus SGLT-2 inhibitors in people with type 2 diabetes: a network meta-analysis. Diabetes Ther. 2017;8(1):85–99. doi:10.1007/s13300-016-0217-4
   PubMed Web of Science ®Google Scholar
• Fadini GP, Sciannameo V, Franzetti I, et al. Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: a multicentre retrospective study. Diabetes Obes Metab. 2019;21(8):1886–1894.
   PubMedGoogle Scholar
• Grabarczyk TR, Wissman NK. Weight outcomes with empagliflozin as compared with liraglutide in veterans with type 2 diabetes mellitus. Ann Pharmacother. 2020;54(10):981–987. doi:10.1177/1060028020915791
   PubMedGoogle Scholar
• Coleman CI, Pandya S, Wang L, et al. Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in type II diabetes patients. J Comp Eff Res. 2019;8(11):889–905. doi:10.2217/cer-2019-0002
   PubMedGoogle Scholar
• Wysham CH, Pilon D, Ingham M, et al. Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting. Curr Med Res Opin. 2018;34(6):1125–1133. doi:10.1080/03007995.2018.1454417
   PubMed Web of Science ®Google Scholar
• Gentilella R, Sesti G, Vazquez L, et al. Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index. Diabetes Obes Metab. 2019;21(12):2660–2666. doi:10.1111/dom.13853
   PubMed Web of Science ®Google Scholar
• Boustani MA, Pittman I, Yu M, Thieu VT, Varnado OJ, Juneja R. Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged >/=65 and <65 years. Diabetes Obes Metab. 2016;18(8):820–828.
   PubMedGoogle Scholar
• Gallwitz B, Dagogo-Jack S, Thieu V, et al. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Diabetes Obes Metab. 2018;20(2):409–418. doi:10.1111/dom.13086
   PubMed Web of Science ®Google Scholar
• Kirkman MS, Rowan-Martin MT, Levin R, et al. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care. 2015;38(4):604–609.
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Nasser SA. Racial/ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus. Curr Med Res Opin. 2015;31(5):913–923. doi:10.1185/03007995.2015.1029894
   PubMed Web of Science ®Google Scholar
• Mishriky BM, Powell JR, Wittwer JA, et al. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(10):2274–2283. doi:10.1111/dom.13805
   PubMed Web of Science ®Google Scholar
• Pantalone KM, Misra-Hebert AD, Hobbs TM, et al. The probability of A1C goal attainment in patients with uncontrolled type 2 diabetes in a large integrated delivery system: a prediction model. Diabetes Care. 2020;43(8):1910–1919. doi:10.2337/dc19-0968
   PubMedGoogle Scholar
• Tran AT, Berg TJ, Gjelsvik B, et al. Ethnic and gender differences in the management of type 2 diabetes: a cross-sectional study from Norwegian general practice. BMC Health Serv Res. 2019;19(1):904. doi:10.1186/s12913-019-4557-4
   PubMedGoogle Scholar
• Campbell JA, Walker RJ, Smalls BL, Egede LE. Glucose control in diabetes: the impact of racial differences on monitoring and outcomes. Endocrine. 2012;42(3):471–482. doi:10.1007/s12020-012-9744-6
   PubMed Web of Science ®Google Scholar
• Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care. 2013;36(8):2271–2279. doi:10.2337/dc12-2258
   PubMed Web of Science ®Google Scholar
• Yu M, Mody R, Lando LF, et al. Characteristics associated with the choice of first injectable therapy among US patients with type 2 diabetes. Clin Ther. 2017;39(12):2399–2408. doi:10.1016/j.clinthera.2017.11.001
   PubMedGoogle Scholar
• Elhussein A, Bancks M, Knowler WC, et al. 37-OR: racial and socioeconomic disparities in the use of newer classes of diabetes medications. Diabetes. 2020;69:37–OR. doi:10.2337/db20-37-OR
   Google Scholar
• Toulis KA, Hanif W, Saravanan P, et al. All-cause mortality in patients with diabetes under glucagon-like peptide-1 agonists: a population-based, open cohort study. Diabetes Metab. 2017;43(3):211–216. doi:10.1016/j.diabet.2017.02.003
   PubMedGoogle Scholar
• Toulis KA, Willis BH, Marshall T, et al. All-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, open-cohort study in the health improvement network database. J Clin Endocrinol Metab. 2017;102(5):1719–1725. doi:10.1210/jc.2016-3446
   PubMed Web of Science ®Google Scholar
• Svanstrom H, Ueda P, Melbye M, et al. Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden. Lancet Diabetes Endocrinol. 2019;7(2):106–114. doi:10.1016/S2213-8587(18)30320-6
   PubMed Web of Science ®Google Scholar
• Longato E, Di Camillo B, Sparacino G, Tramontan L, Avogaro A, Fadini GP. Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice. Cardiovasc Diabetol. 2020;19(1):74.
   PubMedGoogle Scholar
• Yang CT, Yang CY, Ou HT, Kuo S. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study. Cardiovasc Diabetol. 2020;19(1):83. doi:10.1186/s12933-020-01053-0
   PubMedGoogle Scholar
• Pasternak B, Wintzell V, Eliasson B, et al. Use of glucagon-like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study. Diabetes Care. 2020;43(6):1326–1335. doi:10.2337/dc19-2088
   PubMed Web of Science ®Google Scholar
• Tonneijck L, van Raalte DH, Muskiet MHA. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(22):2195.
   PubMedGoogle Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131–138.
   PubMed Web of Science ®Google Scholar
• Longato E, Di Camillo B, Sparacino G, Gubian L, Avogaro A, Fadini GP. Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. BMJ Open Diabetes Res Care. 2020;8(1):e001451. doi:10.1136/bmjdrc-2020-001451
   PubMedGoogle Scholar
• Patorno E, Patrick AR, Garry EM, et al. Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations. Diabetologia. 2014;57(11):2237–2250. doi:10.1007/s00125-014-3364-z
   PubMedGoogle Scholar
• Gokhale M, Sturmer T, Buse JB. Real-world evidence: the devil is in the detail. Diabetologia. 2020:1–12.
   PubMedGoogle Scholar
• Liu Y, De A. Multiple imputation by fully conditional specification for dealing with missing data in a large epidemiologic study. Int J Stats Med Res. 2015;4(3):287–295. doi:10.6000/1929-6029.2015.04.03.7
   PubMedGoogle Scholar
• Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919
   PubMed Web of Science ®Google Scholar
• McAdam-Marx C, Nguyen H, Schauerhamer MB, et al. Glycemic control and weight outcomes for exenatide once weekly versus liraglutide in patients with type 2 diabetes: a 1-year retrospective cohort analysis. Clin Ther. 2016;38(12):2642–2651. doi:10.1016/j.clinthera.2016.11.003
   PubMedGoogle Scholar